Epidemiological, clinical and animal studies indicate non-steroidal anti-inflammatory drugs
(NSAIDs) to be chemopreventive for colorectal cancer. The best established target for …

Cyclooxygenase-2 (COX-2) is upregulated in a number of epithelial cancers, including in
upper aerodigestive tract (UADT) premalignant and malignant lesions. The purpose of this …

Cyclooxygenase (COX) inhibitors are being developed as potential agents for the
prevention and treatment of cancer after a century of widespread use for inflammation, fever …

Summary Expression of cyclooxygenase 2 (COX-2) is believed to play an important role in
adenoma formation in murine polyposis models, and inhibition of COX-2 activity may, at …

Early experiments performed during 1980s and 1990s using carcinogen-induced rat
intestinal tumor models demonstrated the inhibitory effects of non-steroidal anti-inflammatory …

Cancer is predicted to become the leading cause of death–surpassing heart disease–by the
end of this decade. Colorectal cancer is a major health concern, with more than 1,000,000 …

Several lines of evidence suggest that cyclooxygenase-2 (COX-2) is a rational target for
anticancer therapy. Epidemiological studies have shown that use of nonsteroidal anti …

Two events in the last decade have set the stage for the large-scale clinical testing of
chemopreventive agents for colorectal cancer in people at low to moderate risk for this …

Background Epidemiologic and laboratory investigations suggest that aspirin and other
nonsteroidal anti-inflammatory drugs (NSAIDs) have chemopreventive effects against colon …

We conducted a series of epidemiologic studies to evaluate the chemopreventive effects of
aspirin, ibuprofen, and selective cyxlooxygenase-2 (COX-2) inhibitors (coxibs) against …